+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Therapeutics Market by Route Of Administration (Injectable, Oral), Therapy Line (First Line, Second Line, Third Line), Drug Class, Distribution Channel - Global Forecast 2025-2030- Product Image
Gout Therapeutics Market by Route Of Administration (Injectable, Oral), Therapy Line (First Line, Second Line, Third Line), Drug Class, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Gout Therapeutics Market by Route Of Administration (Injectable, Oral), Therapy Line (First Line, Second Line, Third Line), Drug Class, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904565
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gout therapeutics market has experienced significant changes as treatment strategies evolve and new technologies emerge. Decision-makers in the healthcare and pharmaceutical sectors require a comprehensive understanding of the shifting competitive landscape to drive effective development and commercialization initiatives.

Market Snapshot: Gout Therapeutics Market Size and Growth

The Gout Therapeutics Market grew from USD 3.05 billion in 2024 to USD 3.40 billion in 2025 and is projected to expand at a CAGR of 10.99%, reaching USD 5.71 billion by 2030. This robust momentum reflects increasing demand for advanced treatments, supported by ongoing scientific advances and deeper patient-focused approaches. Expansion is reinforced by regulatory flexibility, new delivery technologies, and a strong pipeline of biologics and small molecules that offer differentiated mechanisms and management strategies for both acute and chronic disease.

Scope & Segmentation

This analysis provides detailed segmentation and coverage to enable targeted analysis and strategic planning.

  • Route of Administration: Injectable (intravenous, subcutaneous) and oral therapies, each with unique implications for patient adherence and clinical outcomes.
  • Therapy Line: First-line (nonsteroidal anti-inflammatory drugs, xanthine oxidase inhibitors), second-line (colchicine, uricosuric agents), and third-line (corticosteroids, uricase agents) approaches, aligned to disease severity and response.
  • Drug Class: Anti-inflammatory agents (colchicine, corticosteroids), uricase agents (pegloticase, rasburicase), uricosuric agents (benzbromarone, lesinurad, probenecid), xanthine oxidase inhibitors (allopurinol, febuxostat, topiroxostat).
  • Distribution Channel: Hospital pharmacy (inpatient, outpatient), online pharmacy, and retail pharmacy for integrated patient access strategies.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key Western European countries, the Middle East, and Africa), and Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Company Coverage: Assessment of leading players such as Takeda Pharmaceutical Company Limited, Horizon Therapeutics plc, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Viatris, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals, and Lupin Limited.

Gout Therapeutics Market: Key Takeaways

  • Innovation pipelines are extending beyond symptomatic relief, targeting metabolic pathways for long-term control and offering multiple avenues for disease management.
  • Biologics and novel small molecules are gaining traction, providing new options driven by patient needs and improved safety profiles.
  • Segment-specific strategies enable differentiation, allowing manufacturers to improve market positioning and adapt to evolving prescriber preferences.
  • Collaborative R&D, cross-industry alliances, and integration of digital health platforms enhance value delivery across the ecosystem.
  • Stakeholder collaboration and real-world evidence programs are increasingly critical to optimize patient access and inform reimbursement models.
  • Regional differences in regulatory processes and purchasing power necessitate localized market access planning and tailored pricing approaches.

Impact of Tariff Measures in Gout Therapeutics Supply Chains

The introduction of new tariff measures by the United States in 2025 presents fresh complexities for global gout therapeutics supply chains. Manufacturers must adapt sourcing and logistics strategies to offsets cost increases while safeguarding continuity of supply. Shifts in R&D incentives, pressures to diversify production, and near-shoring considerations now require close coordination between procurement, strategy, and compliance functions. Proactive scenario planning and analytics are essential to protect margins and sustain innovation momentum in this new environment.

Methodology & Data Sources

This report draws on a hybrid methodology, combining extensive secondary research from scientific literature and regulatory databases with qualitative interviews of clinicians, pharmacoeconomists, and supply chain experts. Data triangulation and case benchmarking support accuracy, while scenario modeling ensures actionable, evidence-driven insights for senior stakeholders.

Why This Report Matters

  • Facilitates strategic planning by aligning product development, investment, and go-to-market strategies with evolving market demands.
  • Enables tailored decision-making by offering segment-level context, technology insights, and competitive intelligence grounded in real-world developments.
  • Equips leadership teams with actionable frameworks to navigate regional differences, regulatory changes, and competitive dynamics efficiently.

Conclusion

The gout therapeutics market continues to evolve through targeted innovation, resilient supply chain strategies, and adaptive market access approaches. Informed investment and agile execution will be essential for organizations striving for sustained growth and leadership in this dynamic field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of IL-1 inhibitors for acute gout flare management in high-risk patients
5.2. Market entry of novel URAT1 inhibitors targeting refractory hyperuricemia in chronic gout
5.3. Impact of cardiovascular safety concerns on febuxostat utilization and prescribing patterns
5.4. Integration of digital health platforms for remote monitoring and adherence in gout care
5.5. Real-world evidence shaping cost effectiveness of combination urate-lowering therapies
5.6. Expansion of patient stratification strategies based on genetic polymorphisms affecting gout risk
5.7. Development of next-generation drug delivery systems for sustained gout therapeutics release
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gout Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral
9. Gout Therapeutics Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.2.1. Nonsteroidal Anti-Inflammatory Drug
9.2.1.1. Ibuprofen
9.2.1.2. Indomethacin
9.2.1.3. Naproxen
9.2.2. Xanthine Oxidase Inhibitor
9.2.2.1. Allopurinol
9.2.2.2. Febuxostat
9.3. Second Line
9.3.1. Colchicine
9.3.2. Uricosuric Agent
9.3.2.1. Benzbromarone
9.3.2.2. Lesinurad
9.3.2.3. Probenecid
9.4. Third Line
9.4.1. Corticosteroid
9.4.1.1. Methylprednisolone
9.4.1.2. Prednisone
9.4.2. Uricase Agent
9.4.2.1. Pegloticase
9.4.2.2. Rasburicase
10. Gout Therapeutics Market, by Drug Class
10.1. Introduction
10.2. Anti-Inflammatory Agent
10.2.1. Colchicine
10.2.2. Corticosteroid
10.3. Uricase Agent
10.3.1. Pegloticase
10.3.2. Rasburicase
10.4. Uricosuric Agent
10.4.1. Benzbromarone
10.4.2. Lesinurad
10.4.3. Probenecid
10.5. Xanthine Oxidase Inhibitor
10.5.1. Allopurinol
10.5.2. Febuxostat
10.5.3. Topiroxostat
11. Gout Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Americas Gout Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Gout Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Gout Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Takeda Pharmaceutical Company Limited
15.3.2. Horizon Therapeutics plc
15.3.3. AstraZeneca plc
15.3.4. Teva Pharmaceutical Industries Ltd.
15.3.5. Viatris, Inc.
15.3.6. Sandoz International GmbH
15.3.7. Sun Pharmaceutical Industries Ltd.
15.3.8. Dr. Reddy’s Laboratories Ltd.
15.3.9. Amneal Pharmaceuticals, Inc.
15.3.10. Lupin Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. GOUT THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. GOUT THERAPEUTICS MARKET: RESEARCHAI
FIGURE 24. GOUT THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 25. GOUT THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 26. GOUT THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GOUT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 209. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. CANADA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 212. CANADA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 213. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 214. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 215. CANADA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 216. CANADA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 217. CANADA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 218. CANADA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 219. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 220. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 221. CANADA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 222. CANADA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 223. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 224. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 225. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 226. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 227. CANADA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 228. CANADA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 229. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 230. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 231. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2024 (USD MILLION)
TABLE 234. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2025-2030 (USD MILLION)
TABLE 235. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 236. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 237. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 238. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 239. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 240. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 241. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. CANADA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 244. CANADA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 245. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 248. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 249. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 250. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 251. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 252. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 253. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 254. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 255. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 256. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 257. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 258. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 259. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 260. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 261. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 262. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 263. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 264. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 265. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 266. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 267. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2024 (USD MILLION)
TABLE 270. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2025-2030 (USD MILLION)
TABLE 271. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 272. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 273. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 274. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 275. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 276. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 277. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 280. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 316. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2025-2030 (USD MILLION)
TABLE 327. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 328. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 329. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 330. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 331. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2024 (USD MILLION)
TABLE 332. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2025-2030 (USD MILLION)
TABLE 333. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2024 (USD MILLION)
TABLE 334. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2025-2030 (USD MILLION)
TABLE 335. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 336. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 337. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2024 (USD MILLION)
TABLE 338. ARGENTINA GOUT THERAP

Samples

Loading
LOADING...

Companies Mentioned

  • Takeda Pharmaceutical Company Limited
  • Horizon Therapeutics plc
  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Lupin Limited

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.71 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action (Uricase Agents, Uricosuric Agents, Xanthine Oxidase Inhibitors), Product Type (Branded, Generic), Route Of Administration, Distribution Channel, Dosage Form - Global Forecast 2025-2030 - Product Image

Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action (Uricase Agents, Uricosuric Agents, Xanthine Oxidase Inhibitors), Product Type (Branded, Generic), Route Of Administration, Distribution Channel, Dosage Form - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Gout Disease Treatment - Global Strategic Business Report - Product Image

Gout Disease Treatment - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Gout Therapeutics Market Report 2025 - Product Image

Gout Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gout - Pipeline Insight, 2025 - Product Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Gouty Arthritis Market Report 2025 - Product Image

Gouty Arthritis Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Gout Drug Market

The Gout Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Gout drugs are used to reduce the inflammation and pain associated with gout, a type of arthritis caused by the buildup of uric acid in the joints. These drugs can be taken orally or injected directly into the affected joint. Commonly prescribed gout drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Gout drugs are typically prescribed by a doctor and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the form in which it is taken. Some companies in the Gout Drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.